Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Cartron, G., Dacheux, L., Salles, G. A., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,954

Cetuximab for the Treatment of Colorectal Cancer

Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125

Breast Cancer Pharmacogenetics in the Era of Personalized Medicine

Yao, S., Maghsoudlou, D., & Ambrosone, C. B. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0088-2 · Cited by 4

Development of a real-time PCR detection method for a FCGR2A polymorphism in the LightCycler and application in the heparin-induced thrombocytopenia syndrome

Κroupis, C., Theodorou, M., Kounavi, M., Oliveira, S. C., Iliopoulou, E., Mavri‐Vavayanni, M., Melissari, E. N., & Degiannis, D. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.07.026 · Cited by 4

Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report

Mekata, E., Endo, Y., Sonoda, H., Shimizu, T., Kawai, Y., Umeda, T., Shiomi, H., Naka, S., Kubota, Y., Murata, S., et al. (2013) · Oncology Letters · doi:10.3892/ol.2013.1477 · Cited by 4

The FcγRIIIA‐158 VV genotype increased the risk of post‐transplant lymphoproliferative disorder in T‐cell‐depleted kidney transplant recipients – a retrospective study

Gatault, P., Lajoie, L., Stojanova, J., Halimi, J., Caillard, S., Moyrand, S., Martinez, D., Ladrière, M., Morélon, E., Merville, P., et al. (2020) · Transplant International · doi:10.1111/tri.13624 · Cited by 4

The Case for Selective Use of Pre-Operative Chemotherapy for Hepatic Colorectal Metastases: More Is Not Always Better

Karakousis, G. C., & Fong, Y. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0539-9 · Cited by 4

Facts and Hopes in Harnessing Macrophage-Mediated Antibody-Dependent Cellular Phagocytosis for Cancer Immunotherapy

Armero, M., Smolkin, M., García‐Domínguez, M., Berraondo, P., Melero, I., & Gálvez‐Cancino, F. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0434 · Cited by 3

Can the “Right” EGFR-Specific mAb Dramatically Improve EGFR-Targeted Therapy?

Sabbatino, F., & Ferrone, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3586 · Cited by 3

Anticorps monoclonaux à usage thérapeutique : spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long terme

Paintaud, G., Diviné, M., Lechat, P. P., Bagot, M., Boucot, I. H., d’Andon, A., Grudé, F., Lecomte, T., Liu-Léage, S., Olive, D., et al. (2012) · Therapies · doi:10.2515/therapie/2012043 · Cited by 3

Transfection of FcγRIIIa (CD16) Alone Can Be Sufficient To Enable Human αβTCR T Lymphocytes To Mediate Antibody-Dependent Cellular Cytotoxicity

Ollier, J., Vivien, R., Vié, H., & Clemenceau, B. (2017) · ImmunoHorizons · doi:10.4049/immunohorizons.1700022 · Cited by 3

Novel cancer‐specific epidermal growth factor receptor antibody obtained from the serum of esophageal cancer patients with long‐term survival

Takagi‐Maeda, S., Yajima, S., Suzuki, T., Usami, K., Takahashi, N., Niwa, R., & Shimada, H. (2022) · Cancer Science · doi:10.1111/cas.15350 · Cited by 3

Optimising the Development of Antibodies as Treatment for Cancer

Carden, C. P., Arkenau, H., & Bono, J. S. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7358-0_19 · Cited by 3

Why Cetuximab is Not Active in the Adjuvant Setting

Murray, J. C., Wu, C. S.-Y., & Weiner, L. M. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0103-4 · Cited by 2

In Situ Tumor Surface Modification with Antibody Fragments for Antigen-Independent Versatile Cancer Immunotherapy

Kang, S., Kang, Y., Lee, Y., Park, J., Lee, J., & Kim, W. J. (2025) · ACS Nano · doi:10.1021/acsnano.5c08128 · Cited by 2

Molecular Targeted Therapies in Head and Neck Cancer

Gondi, V., Traynor, A. M., & Harari, P. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9464-6_20 · Cited by 2

Selecting the best targeted agent in first‐line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?

Benhaïm, L., Loupakis, F., LaBonte, M. J., & Lenz, H. (2012) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-012-0526-6 · Cited by 3

Incidence of KRAS status in ongoing adjuvant trials in colon cancer

Taïeb, J., Laurent‐Puig, P., & Alberts, S. R. (2009) · Current Colorectal Cancer Reports · doi:10.1007/s11888-009-0025-6 · Cited by 2

Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety

Paintaud, G., Diviné, M., Lechat, P. P., Bagot, M., Boucot, I. H., d’Andon, A., Grudé, F., Lecomte, T., Liu-Léage, S., Olive, D., et al. (2012) · Therapies · doi:10.2515/therapie/2012046 · Cited by 2

GlycoOptimization for Fully Human and Largely Improved Biopharmaceutical Antibodies and Proteins

Goletz, S., Danielczyk, A., Stahn, R., Karsten, U. R., Stöckl, L., Löffler, A., Hillemann, A., & Baumeister, H. (2010) · Cited by 2

Approaches to Immunologic Monitoring of Clinical Trials

Butterfield, L. H., Vujanovic, L. N., & Pardee, A. D. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_29 · Cited by 2

Antibody Engineering

Lo, K.-M., Léger, O. J. P., & Hock, B. M. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch19 · Cited by 2

Cancer colorectal métastatique et thérapies ciblées

Fiore, F. D., oden-Gangloff, A., & Michel, P. (2009) · Côlon & Rectum · doi:10.1007/s11725-009-0185-1 · Cited by 2

Droplet-Digital PCR Provides a Rapid, Accurate and Cost-Effective Method for Identification of Biomarker FcγRIIIa-F158V Genotypes

Griffith, P., Sun, D., Tritsch, S. R., Jochéms, C., Gulley, J. L., Schlom, J., & Wu, X. (2017) · Gene Technology · doi:10.4172/2329-6682.1000143 · Cited by 2

NK Cells in Antitumor Immunity

Cerwenka, A., & Pahl, J. H. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17012-2 · Cited by 2

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition

Ottaiano, A., Capuozzo, M., Nasti, G., Maiolino, P., Angelis, V. D., Scala, S., & Iaffaioli, R. V. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00409 · Cited by 1

Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality

Twomey, J. D., George, S., & Zhang, B. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf003 · Cited by 1

CAR-NK cells for haematological cancers.

Noorafrooz, M., Gale, R. P., Noorafrooz, R., & Ghods, S. (2025) · Baillière's Best Practice & Research: Clinical Haematology · doi:10.1016/j.beha.2025.101631 · Cited by 1

Use of a Foamy‐Virus Vector System to Produce an ‘Off‐the‐Shelf’ Fcγ‐ CR ‐T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies

Λαζανά, Ι., Simantirakis, E., Kourous, E., Daniil, M., Ioannou, D., & Vassilopoulos, G. (2025) · Immunology · doi:10.1111/imm.70018 · Cited by 1

Réponses aux thérapies ciblées : le cancer colorectal

Bibeau, F., Frugier, H., & Boissière‐Michot, F. (2009) · Annales de Pathologie · doi:10.1016/j.annpat.2009.07.034 · Cited by 1

The Cost-Effectiveness of Combination Treatment Consisting of Either Cetuximab or Panitumumab plus FOLFIRI versus Treatment with Bevacizumab plus FOLFIRI as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer Patients in Ontario

Ewara, E. M. (2012) · Scholarship@Western (Western University) · Cited by 1

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction

Kuehnle, M.-C., Attig, S., Britten, C. M., Schulze‐Bergkamen, H., Lordick, F., von Wichert, G., Thuss-Patience, P. C., Stein, A., Schüler, M., Bassermann, F. C., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1596-x · Cited by 1

Progressive Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Cell Transplantation

Jitawatanarat, P., Desai, A., Sharda, P., Liu, H., Ross, M., Hernandez‐Ilizaliturri, F. J., McCarthy, P. L., & Chen, G. L. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0127 · Cited by 1

Anticorps monoclonaux en oncologie : déclencher une réponse immunitaire en plus de la réduction tumorale spécifique.

Goubet, A., Derosa, L., Marabelle, A., & Zitvogel, L. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30321-8 · Cited by 1

Antibody Fc engineering for optimal antibody performance

(2012) · Elsevier eBooks · doi:10.1533/9781908818096.225 · Cited by 1

Glyco-engineered Therapeutic Antibodies as a Second-Generation Antibody Therapy

Niwa, R., Shitara, K., & Satoh, M. (2014) · Springer eBooks · doi:10.1007/978-4-431-54841-6_196 · Cited by 1

Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer

Monzon, J. G., & Dancey, J. E. (2020) · doi:10.1201/9781003159469-7 · Cited by 1

Novel Generation of Antibody-Based Therapeutics

Brezski, R. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00006-7 · Cited by 1

FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment

Chae, H., Yoo, C., Yoon, J.-A., Lee, H. J., Kim, K., Kim, J., Ahn, J., Jung, K. H., Gong, G., & Kim, S. (2018) · Journal of Breast Cancer · doi:10.4048/jbc.2018.21.1.45 · Cited by 1

Monoclonal Antibodies for the Treatment of Cancer

Weiner, L. M., & Surana, R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00050-0 · Cited by 1

Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy

Riller, Q., Varthaman, A., & Sibéril, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_9 · Cited by 1

High-Density of FcγRIIIA+ (CD16+) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis

Musquer, M. D., Jouand, N., Péré, M., Eugene-Lamer, J., Bezieau, S., Matysiak‐Budnik, T., Faroux, R., Caroli‐Bosc, F., Rousselet, M., Leclair, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684478 · Cited by 1

Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer

Monzon, J. G., & Dancey, J. E. (2013) · Pan Stanford Publishing eBooks · doi:10.1201/b15029-8 · Cited by 1

The Cetuximab Experience: Developing Predictive Biomarkers in Oncology

Harbison, C. T., Horak, C. E., & Khambata‐Ford, S. (2011) · Personalized Medicine · doi:10.2217/pme.10.78 · Cited by 1

Reply to T. Valerius

Shepherd, F. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8589 · Cited by 1

Fc Engineering

Peipp, M., Derer, S., Lohse, S., Kellner, C., & Valerius, T. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch7 · Cited by 1

References

(2012) · Elsevier eBooks · doi:10.1016/b978-1-907568-37-4.50029-4 · Cited by 1

Targeted Therapeutics in Cancer Treatment

Weekes, C. D., & Hidalgo, M. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7358-0_15

Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology

Landes, G. M., & Elias, K. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_8

Regulation by IL-10 of innate immune responses to MUC1 as a self-antigen in MUC1 transgenic mice

Marvel, D. (2014) · D-Scholarship@Pitt (University of Pittsburgh)

The Treatment of Metastatic Liver Disease of Colorectal Origin

Tsoulfas, G., & Manousos-Georgios, P. (2011) · InTech eBooks · doi:10.5772/24543

Marqueurs moléculaires prédictifs de réponse aux thérapies ciblées dans les cancers digestifs

Perkins, G. (2012) · theses.fr (ABES) · doi:10.70675/5b4631efzc0e5z4dddz8408z43ab410793f3

Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics

Caraglia, M., Nicoletti, G. F., Lombardi, A., Botti, G., & Franco, R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7357-2_3

Polimorfismos del receptor Fc gamma en patología cutánea inmunomediada: Papel en la patogenia del penfigoide ampolloso y en la respuesta a tratamiento biológico en la psoriasis

Vidal, A. G. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

Anatomie pathologique : en marche vers l’analyse moléculaire

Fléjou, J., & Cervera, P. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.07.011

Reply to T. Valerius

Horak, C. E., Harbison, C. T., & Khambata‐Ford, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9462

A New Predictive Molecular Marker for Cetuximab Benefit in Rectal Cancer?

George, T. J., & O’Connell, M. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju154

La recherche clinique en cancérologie digestive: de la cible à la véritable personnalisation du traitement?

Metges, J., Volant, A., Grudé, F., Pradier, O., Riché, C., Gamelin, E. C., & Corcos, L. (2009) · ONCOLOGIE · doi:10.1007/s10269-009-1079-4

Targeted Therapies For Intestinal Tumorigenesis

Chiorean, E. G., Coveler, A. L., Grim, J. E., & Grady, W. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19986-3_13

Personalisation of therapy in advanced colorectal cancer

Seligmann, J. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)

La recherche clinique en cancerologie digestive : de la cible al a veritable personnalisation du traitement ?

Bretagne-Pays-de-la-Loire, O. (2009)

Development of new tools for genomic biomarker investigations

Zanda, V. (2011) · BOA (University of Milano-Bicocca)

Fc Gamma R

Simpson, T. R., & Allison, J. P. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_140

Wahl der Behandlungsstrategie auf der Basis molekularer Marker

Stintzing, S., & Heinemann, V. (2015) · Im Focus Onkologie · doi:10.1007/s15015-015-1827-9

Pharmacological Advances in Metastatic Colorectal Cancer Management

Cassidy, J. (2011) · doi:10.2217/9781780840086

Charakterisierung rekombinanter IgA-Antikörper gegen den EGFR

Lohse, S. (2010) · Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel)

Pharmacogenetics of advanced colorectal cancer treatment

Pander, J. (2010) · Leiden Repository (Leiden University)

ADCC Enhancement Technologies for Next‐Generation Therapeutic Antibodies

Liu, C., & Yan, S. (2016) · doi:10.1002/9781118940648.ch20

Farmacogenética en el tratamiento del cáncer colorrectal

López-Bravo, D. P. (2012) · TDX (Tesis Doctorals en Xarxa)

Characterisation and development of 2448 and C51 : novel monoclonal antibodies targeting ovarian and breast cancer

Cua, S. (2017) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/72381

The Treatment of Colorectal Carcinoma With Monoclonal Antibodies: Subsequent Immunological Mechanisms

Tsamaloukas, A. G. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0526a

Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer

Weickhardt, A. J. (2011) · Minerva Access (University of Melbourne)

Optimising Oncolytic Virotherapy and Immunotherapy for the treatment of Disseminated Colorectal Cancer

Peckham-Cooper, A. (2017) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)

Monoclonal Antibody Therapy

Mittendorf, E. A., & Prabhakaran, S. (2018) · doi:10.1002/9781118684535.ch2

The Treatment of Colorectal Carcinoma With Monoclonal Antibodies: In reply

Heinemann, V., & Stintzing, S. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0526b

Refining natural killer cell-based immunotherapy

van Eijl, M. (2018) · Research Publications (Maastricht University) · doi:10.26481/dis.20181219nm

TAO Kinase 3 Overexpression Is a Poor Prognosis Marker for Lung Adenocarcinoma and Predicts Paclitaxel ResistancePreprint

Lai, T., Yang, Y., Chang, Y., Chiou, J., Huang, M., Yang, C., Chang, P. M., & Hsiao, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622621

Regulation of Anti-tumor Immunity in Colorectal Cancer by Interaction of Exosome Immune Complexes with Fc gamma Receptors

McNamara, A. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-5838-dr52

The therapeutical approaches for rare diseases through the immune processes of IgG Fc Receptors

Wu, Z. H. (2020) · Global Journal of Medical and Clinical Case Reports · doi:10.17352/2455-5282.000104

Understanding relevant immune mechanisms in gastrointestinal oncology

Çetin, B., & Gümüşay, Ö. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155221992862

Advances in pluripotent stem cell-derived natural killer cells for cancer immunotherapy

Coffey, M., Yamamoto, K., & Kaufman, D. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00008-4

In vitro determination and functional maturation of natural killer cells from umbilical cord blood progenitor cells

Pinho, M. J. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/b35a-e035

Colorectal Cancer

Church, D. N., Midgley, R. S., & Kerr, R. S. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_9 · Cited by 1

Fc Gamma R

Simpson, T. R., & Allison, J. P. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_140-1

Molecular Targeted Therapies in Head and Neck Cancer

Morris, Z. S., Traynor, A. M., & Harari, P. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27601-4_20

Monoclonal antibodies

Tonini, G., Imperatori, M., Zoccoli, A., Iuliani, M., & Pantano, F. (2011) · doi:10.2217/ebo.11.98

Glyco-engineered Therapeutic Antibodies as a Second-Generation Antibody Therapy

Niwa, R., Shitara, K., & Satoh, M. (2014) · Springer eBooks · doi:10.1007/978-4-431-54836-2_196-1

Antibody interactions with the immune system

(2012) · Elsevier eBooks · doi:10.1533/9781908818096.131

Pharmacogénétique et thérapies ciblées

Milano, G. A., & Étienne-Grimaldi, M.-C. (2014) · Springer eBooks · doi:10.1007/978-2-8178-0445-3_8

Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in Cancer

Paccagnella, M., Abbona, A., Denaro, N., Merlano, M. C., & Garrone, O. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_11-1 · Cited by 1

Assessment of the impact of FcγRIIIA single-nucleotide polymorphisms on the efficacy of IgG1 monoclonal antibodies in patients with advanced gastroesophageal adenocarcinoma

Serritella, A. V., Grewal, N., Peterson, B., Arndt, K., del Gaudio, D., Liu, P., Shergill, A. P., Polite, B. N., Kindler, H. L., Catenacci, D. V. T., et al. (2023) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.08.011

Perspective view of allogeneic IgG tumor immunotherapy

Liu, Y., Huang, Y., Cui, H., Wang, Y., Ma, Z., Xiang, Y., Xin, H.-Y., Liang, J., & Xin, H.-W. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03290-9

The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cellsPreprint

Villalba, M., Constantinides, M., Coënon, L., de Maudave, A. F., Multrier, C., Campos‐Mora, M., Jacquard, C., Gao, F., Martineau, P., Robert, B., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4017845/v1

Additional file 6 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

Meng, F., Zhang, S., Xie, J., Zhou, Y., Wu, Q., Lu, B., Zhou, S., Zhao, X., & Li, Y. (2023) · Figshare · doi:10.6084/m9.figshare.23520083

Monoclonal Antibodies-Based Approaches in Cancer Immunotherapy

Mehta, A., Kulkarni, N. V., & Khot, S. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-7022-9_8

Precision cancer immunotherapy

Galal, A. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-800684-9.00019-8

Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in Cancer

Paccagnella, M., Abbona, A., Denaro, N., Merlano, M. C., & Garrone, O. (2025) · Springer eBooks · doi:10.1007/978-3-032-00749-0_11

FcγRIIa in autoimmunity: Unraveling pathogenic mechanisms and therapeutic opportunities

Zhu, B., Cao, X., Wang, X., Yu, L., Zhou, W., Zhu, L. J., Yang, Q., & Rui, K. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103974

Biological Treatments (Antibodies)

Paradise, W. A., & Radosevich, J. A. (2013) · Springer eBooks · doi:10.1007/978-94-007-5827-8_29

Targeting the Tumor Microenvironment to Enhance the Efficacy of Tumor-Targeted Antibody Therapy

Surana, R. (2014) · DigitalGeorgetown (Georgetown University Library)

Additional file 4 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

Meng, F., Zhang, S., Xie, J., Zhou, Y., Wu, Q., Lu, B., Zhou, S., Zhao, X., & Li, Y. (2023) · Figshare · doi:10.6084/m9.figshare.23520074

Additional file 3 of Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

Meng, F., Zhang, S., Xie, J., Zhou, Y., Wu, Q., Lu, B., Zhou, S., Zhao, X., & Li, Y. (2023) · Figshare · doi:10.6084/m9.figshare.23520071

Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan

Bibeau, F., Crapez, E., Fiore, F. D., Thézenas, S., Sabourin, J., Lamy, A., Frébourg, T., Michel, P., Ychou, M., & Boissière‐Michot, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11004 · Cited by 23

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

Park, S., Hong, Y. S., Lee, J., Ryu, M., Chang, H. M., Kim, K., Ahn, Y., Na, Y.-S., Jin, D., Yu, C. S., et al. (2012) · Oncology · doi:10.1159/000335959 · Cited by 25

Role of polymorphic fc gamma receptor II/III in the efficacy of cetuximab in KRAS-NRAS-BRAF-PI3K mutated.

García‐Foncillas, J., Rodriguez, J., Boni, V., Sola, I., Honorato, B., Zárate, R., & Bandrés, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.477

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

Rodríguez, J., Zárate, R., Bandrés, E., Boni, V., Hernandez, A. B., Sola, J. J., Honorato, B., Bitarte, N., & García‐Foncillas, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.007 · Cited by 82

Fc gamma receptor polymorphisms and KRAS status as predictive biomarkers in patients with metastatic colorectal cancer treated with biweekly cetuximab-based salvage therapy.

Zárate, R., Bandrés, E., Rodriguez, J., Bitarte, N., Honorato, B., Boni, V., Sola, I., Ponz‐Sarvisé, M., Garzón, C., & García‐Foncillas, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13523